1 |
K. Kariko, M. Buckstein, H. Ni & D. Weissman, (2005). Suppression of RNA Recognision by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Cell, 23, 165-175.
DOI
|
2 |
Centers for Disease Control and Prevention. (2021). Fact Sheet for Healthcare Providers Administering Vaccine Energency Use Authorization of the Moderna COVID-19 Vaccine to Prevent COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html
|
3 |
E. Cott, E. deBruyn & J. Coru. (2021). How Pfizer Makes Its Covid-19 Vaccine. New York Times. https://www.nytimes.com/interactive/2021/health/pfizer-coronavirus-vaccine.html
|
4 |
D. Lowe. (2021). RNA Vaccines and Thier Lipids. https://blogs.sciencemag.org/pipeline/archives/2021/01/11/rna-vaccines-and-their-lipids (accessed May 24, 2021)
|
5 |
Centers for Disease Control and Prevention. (2021). Fact Sheet for Recipients and Caregivers Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to Prevent COVID-19 in Individuals 12 Years of Age and Older. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html
|
6 |
C. Zeng, C. Zhang, P. G. Walker & Y. Dong. (2020). Formulation and Delivery Technologies for mRNA Vaccines, Current Topics in Microbiology and Immunology. In: Current Topics in Microbiology and Immunology. Berlin, Heidelberg : Springer. DOI: 10.1007/82_2020_217.
|
7 |
M. Terry. (2021). Updated Comparing COVID-19 Vaccines: Timelines, Types and Prices. Biospace. https://www.biospace.com/article/comparing-covid-19-vaccines-pfizer-biontech-moderna-astrazeneca-oxford-j-and-j-russia-s-sputnik-v/
|
8 |
Y. Wang, Z. Zhang. X. Luo, Y. Han & X. Wei. (2021). mRNA Vaccine: A Potential Therapeutic Strategy, Molecular Cancer, 20, 33.
DOI
|
9 |
C. Calisher et al. (2020). Statement in Support of the Scientists, Public Health Professionals, and Medical Professionals of China Combatting COVID-19. The Lancet, 395(10226), E42-E43.
DOI
|
10 |
M. Bird. (2021-05-06). A Global Operation Warp Speed is Needed to Unlock World-Wide Vaccine Production. Wall Street Journal. https://www.wsj.com/articles/a-global-operation-warp-speed-is-needed-to-unlock-world-wide-vaccine-production-11620285441 (accessed May 24, 2021)
|
11 |
K. Oh. (2018). A Study on the Publication of Open Access Artcles. Journal of the Korean Convergence Society, 11(5), 145-151. DOI: 10.15207/JKCS.2020.11.5.145
DOI
|
12 |
J. Gale & L. Beyer. (2021). What's the Best Covid Vaccine? Why It's not So Simple. Bloomberg. https://www.bloomberg.com/news/articles/2021-03-10/what-s-the-best-covid-vaccine-why-it-s-not-so-simple-quicktake
|
13 |
F. Amant & F. Krammer. (2020). SARS-Cov-2 Vaccines: Status Report. Immunity, 52(4), 583-589. DOI:https://doi.org/10.1016/j.immuni.2020.03.007
DOI
|
14 |
World Health Organization. (2020). COVID-19 Vaccines. WHO Guidance Document. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines (accessed May 24, 2021)
|
15 |
J. Cohen. (2021). Unveiling 'Warp Speed', the White House's America-first Push for a Coronavirus Vaccine. Science. doi:10.1126/science.abc7056
DOI
|
16 |
Springer Nature. (2021). Messengers of Hope. Nat Biotechnol, 39, 1. https://doi.org/10.1038/s41587-020-00807-1
DOI
|
17 |
European Medicines Agency. (2020). COVID-19 Vaccines. EPA Human Regulatory. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines
|
18 |
European Medicines Agency. (2021). Assessment Report COVID-19 Vaccine AstraZeneca. EMA Human Regulatory. https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf
|
19 |
C. Scheitz & L. Leidinger. (2021). Exploring the Supply Chain of the Pfizer/BioNTech and Moderna COVID-19 Vaccines. https://blog.jonasneubert.com/2021/01/10/exploring-the-supply-chain-of-the-pfizer-biontech-and-moderna-covid-19-vaccines/
|
20 |
European Medicines Agency. (2020). Assessment Report COVID-19 Vaccine Janssen.. EMA Human Regulatory. https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf
|
21 |
L. A. Brito et al. (2014). A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines, Molecular Therapy, 22(12), 2118-2129.
DOI
|
22 |
M. Wadman. (2020). Will A Small, Long-shot U.S. Company End Up Producing the Best Coronavirus VAccine. Science. https://www.sciencemag.org/news/2020/11/will-small-long-shot-us-company-end-producing-best-coronavirus-vaccine DOI:10.1126/science.abf5474
DOI
|
23 |
H. H. Tayeb & F. Sainsbury. (2018). Nanoemulsions in Drug Delivery: Formation to Medical Application, Nanomedicine, 13(19), 2507-2525. DOI: 10.2217/nnm-2018-0088
DOI
|
24 |
Y. Singh et al. (2017). Nanoemulsion: Concepts, Development and Applications in Drug Delivery, Journal of Controlled Release, 252, 28-49.
DOI
|
25 |
K. J. Hassett et al. (2021). Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines, Molecular Therapy: Nucleic Acids, 15, 1-11.
DOI
|
26 |
Moderna Extends Lipid Supply for Coronavirus Vaccine (2020). CordenPharma. https://www.cordenpharma.com/CordenPharma_and_Moderna_Extend_Lipid_Supply_Agreement_for_Moderna_Vaccine_mRNA-1273_Against_Novel_Coronavirus_SARS-CoV-2
|
27 |
E. Gray. (2020). NASA Supercomputers Power COVID-19 Research. https://www.nasa.gov/feature/esd/2020/nasa-supercomputers-power-covid-19-research
|
28 |
Advancing Medical Research. (2021). How RNA Technology Could Revolutionize Vaccine Production, Breakthroughs. https://www.breakthroughs.com/advancing-medical-research/how-rna-technology-could-revolutionize-vaccine-production
|
29 |
M. D. Buschmann, M. J. Carrasco, S. Alishetty, M. Paige, M. G. Alameh & D. Weissman, (2021). Nanomaterial Delivery Systems for mRNA Vaccines, Vaccines, 9, 65.
DOI
|
30 |
A. Wolff et al. (1990). Direct Gene Transfer into Mouse Muscle in vivo. Science, 247 (4949 Pt 1), 1465-1468.
DOI
|
31 |
S. K. Gupta, B. J. Haigh, F. J. Griffin & T. T. Wheeler. (2013). The Mammalian Secreted RNases: Mechanismz of Action in Host Defence. Innate Immunity, 19(1), 86-97.
DOI
|
32 |
H. J. Park, H. L. Ko, S. Y. Jung, H. B. Jo & J. H. Nam. (2016). The Characteristics of RNA Vaccine; its Strengths and Weaknesses. Journal of Bacteriology and Virology, 46(3), 115-127.
DOI
|